
ANAPTYSBIO, INC
100
Recent developments include the company's Q3 2026 earnings and revenue miss, a Q2 2026 profit swing due to a tax benefit, and ongoing operational and legal updates.
- ANAPTYSBIO reported missing Q3 2026 earnings and revenue as of November 12, 2026 [N1].
- The company swung to profit in Q2 2026 reflecting a $181.5 million tax benefit [N5].
- ANAPTYSBIO reported a Q2 2026 loss but topped revenue as of September 21, 2026 [N6].
- The company authorized a $100 million stock repurchase plan [N5].
ANAPTYSBIO, INC operates as a biopharmaceutical company with a business model centered on collaborations for drug development and commercialization. The company primarily earns royalties from GSK's commercialization of Jemperli, an immunotherapy product approved in multiple countries. GSK is responsible for all clinical development, regulatory approvals, manufacturing, and commercialization activities related to Jemperli. ANAPTYSBIO also has a collaboration with Vanda for Quimilza, which may contribute to future revenues upon regulatory approval and commercialization. The company operates with no employees, relying on consultants and key executives. The Board of Directors is composed of experienced industry professionals with defined committee structures overseeing audit, compensation, and governance. The company maintains strong liquidity with significant cash reserves and low current liabilities as of September 30, 2026. The business is subject to risks related to dependence on collaborators, competition, regulatory and reimbursement environments, and ongoing litigation.
ANAPTYSBIO, INC is a biopharmaceutical company primarily deriving revenues from royalties on Jemperli, commercialized by GSK under a collaboration agreement. The company reported net income of $3.876 million and EPS of $0.13 basic for the quarter ended September 30, 2026, with strong liquidity ratios (current ratio 8.4, cash ratio 6.04). The business model is highly dependent on GSK's successful commercialization and development of Jemperli, with risks including competition, regulatory developments, and pricing pressures. The company is engaged in litigation related to its collaboration agreement with Tesaro. Recent news highlights include a Q3 earnings and revenue miss reported in November 2026 and a Q2 profit swing reflecting a significant tax benefit. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
ANAPTYSBIO benefits from a streamlined business model focused on royalty income from GSK's commercialization of Jemperli, which has regulatory approvals in multiple countries. The company's strong liquidity position and recent profitability reflect operational efficiency and financial discipline. The collaboration with GSK leverages their commercial capabilities, reducing ANAPTYSBIO's operational burden. The company's Board and management have extensive industry experience, supporting strategic oversight. The potential for additional revenues from collaborations such as with Vanda could diversify income streams. The company's stock repurchase plan indicates confidence in capital allocation.
ANAPTYSBIO's heavy reliance on GSK for the commercialization and development of Jemperli exposes it to significant risks if GSK reduces resources or reprioritizes its oncology portfolio. Competition from established products like Keytruda and emerging therapies could reduce royalty revenues. Regulatory setbacks, pricing pressures from payors and governments, and adverse safety findings could negatively impact sales and royalties. The company faces ongoing litigation related to its collaboration agreements, which could create uncertainty and financial burden. The absence of employees and dependence on consultants may limit operational flexibility. Market volatility and insider sales have been noted, reflecting potential investor concerns.
ANAPTYSBIO's moat is primarily derived from its royalty-based revenue model tied to GSK's commercialization of Jemperli, an approved immunotherapy product in oncology. The company's business model reduces operational complexity by outsourcing development and commercialization to established partners, allowing focus on royalty generation. The collaboration with GSK provides access to a broad oncology portfolio and commercial infrastructure. However, the moat is vulnerable to competitive pressures from other oncology products, potential regulatory changes, and the company's dependence on the success and strategic priorities of its collaborators. Intellectual property rights and ongoing litigation also influence the company's competitive position.
• Dependence on GSK for Commercialization and Development: ANAPTYSBIO derives substantially all revenues from royalties on Jemperli, commercialized by GSK. The company's financial results depend heavily on GSK's successful development, regulatory approvals, marketing, and sales efforts. Any reduction in GSK's resource allocation or reprioritization could materially harm ANAPTYSBIO's business.
• Competition in Oncology Markets: Jemperli faces substantial competition from existing and emerging oncology products, including Keytruda. Competitive pressures could reduce market share and royalty revenues, adversely affecting the company's financial performance.
• Regulatory and Pricing Risks: Adverse regulatory developments, safety concerns, or changes in treatment guidelines could limit Jemperli's market potential. Pricing pressures from governments, payors, and healthcare cost containment initiatives may reduce revenues.
• Litigation and Intellectual Property Uncertainty: The company is involved in litigation with Tesaro regarding the GSK Agreement, which could affect intellectual property rights and financial position. Legal disputes may distract management and incur significant costs.
• Operational Dependence on Limited Personnel: ANAPTYSBIO operates with no employees and relies on a limited number of consultants and key executives, which may constrain operational flexibility and execution.
Business trends: Continued reliance on GSK for Jemperli royalties amid competitive oncology market and regulatory challenges.
Execution milestones: Monitoring outcomes of ongoing litigation, maintaining collaborations, and managing liquidity.
Key risks: Dependence on collaborator performance, regulatory and pricing pressures, competition, and litigation uncertainties.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- ANAPTYSBIO, INC is a biopharmaceutical company with a business model heavily dependent on collaborations, primarily with GSK for commercialization of Jemperli.
- The company derives substantially all of its revenues from royalties from GSK's commercialization of Jemperli, which represents a substantial portion of its revenues.
- ANAPTYSBIO has a collaboration agreement with GSK under which GSK is responsible for development, regulatory approval, manufacturing, and commercialization of Jemperli.
- The company also has a collaboration with Vanda for Quimilza, which may contribute to future revenues if approved and commercialized.
- ANAPTYSBIO operates with no employees and depends on a limited number of consultants and key executives.
- The company has a classified Board of Directors with six members divided into three classes, with detailed biographies and committee memberships disclosed.
- The company has an audit committee, compensation committee, and nominating and corporate governance committee, each with defined responsibilities and composed of independent directors.
- As of September 30, 2026, the company reported cash and cash equivalents of $135.4 million, current assets of $188.4 million, current liabilities of $22.4 million, a current ratio of 8.4, and a cash ratio of 6.04, indicating strong liquidity.
- For the quarter ended September 30, 2026, the company reported net income of $3.876 million and basic and diluted EPS of $0.13 and $0.11 respectively.
- The company is involved in ongoing litigation with Tesaro related to the GSK Agreement, including claims of material breach and ownership of intellectual property rights.
- The company disclosed risks including heavy dependence on GSK's successful commercialization of Jemperli, potential competition from other oncology products including Keytruda, and regulatory and reimbursement risks.
- Royalty revenues from Jemperli may fluctuate due to factors outside the company's control including sales and marketing efforts by GSK, market acceptance, competition, pricing, payor coverage, and regulatory developments.
- The company disclosed that GSK has discretion over resources devoted to Jemperli and may reprioritize commercial programs, which could materially harm ANAPTYSBIO's business.
- The company disclosed that adverse regulatory developments or safety findings related to Jemperli could harm its business.
- Pricing pressures from governments, payors, and healthcare cost containment initiatives may negatively impact royalties.
- The company completed a spin-off of its biopharma operations in Q2 2026 and focuses on royalties.
- Recent news includes Q3 earnings and revenue results reported on November 12, 2026, with the company missing earnings and revenue estimates for that quarter.
- The company swung to profit in Q2 2026 reflecting a $181.5 million tax benefit.
- The company reported a Q2 loss but topped revenue estimates as of September 21, 2026.
- The company authorized a $100 million stock repurchase plan.
- The company has experienced stock price volatility and insider sales have been reported.
- The company is not a large accelerated filer and is classified as a smaller reporting company.
- The aggregate market value of voting common equity held by non-affiliates was approximately $432.5 million as of June 30, 2025, with 29.1 million shares outstanding as of April 23, 2026.
Generated 2026-11-13
- S1
- S2
- S1 | 2026-04-28 | 10-K/A
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/anaptysbio-inc-anab-misses-q3-earnings-and-revenue-estimates
- N2 | 2026-11-12 | www.nasdaq.com | EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/eyepoint-eypt-reports-q3-loss-beats-revenue-estimates
- N3 | 2026-10-28 | www.nasdaq.com | Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth | https://www.nasdaq.com/articles/arcutis-biotherapeutics-inc-arqt-reports-next-week-wall-street-expects-earnings-growth
- N4 | 2026-10-20 | www.nasdaq.com | CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research | https://www.nasdaq.com/articles/cytodyn-appoints-robert-e-hoffman-ceo-lalezari-focus-research
- N5 | 2026-09-22 | www.nasdaq.com | AnaptysBio Swings To Profit In Q2 Reflecting $181.5 Mln Tax Benefit | https://www.nasdaq.com/articles/anaptysbio-swings-profit-q2-reflecting-1815-mln-tax-benefit
- N6 | 2026-09-21 | www.nasdaq.com | AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/anaptysbio-inc-anab-reports-q2-loss-tops-revenue-estimates
- N7 | 2026-08-13 | www.nasdaq.com | CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/cormedix-crmd-q2-earnings-and-revenues-top-estimates
- N8 | 2026-05-11 | www.nasdaq.com | RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus | https://www.nasdaq.com/articles/rckt-stock-down-q1-earnings-miss-kresladi-launch-focus
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


